Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 2,101–2,200 of 2,517
[Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer].
Wang, R., Pan, S., & Song, X. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.06 · Cited by 5
The Li–Fraumeni syndrome and the role of TP53 mutations in predisposition to cancer
Birch, J. M. (2004) · CRC Press eBooks · doi:10.1201/b13271-15 · Cited by 2
Jacobsen, D. R., Bushara, O., Mishra, R. K., Sun, L., Liao, J., & Yang, G. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.07.005 · Cited by 2
Genetic Counseling, Polymorphisms and Breast Cancer
e, S. K. S. F. (2019) · Journal of Family Medicine and Disease Prevention · doi:10.23937/2469-5793/1510098 · Cited by 3
Papaleo, E. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-1154-8_13 · Cited by 2
Bizzarri, A. R., & Cannistraro, S. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c05909 · Cited by 2
Binding Promiscuity of Unfolded Peptides
Oldfield, C. J., Xue, B., Dunker, A. K., & Uversky, V. N. (2012) · Wiley eBooks · doi:10.1002/9781118183373.ch9 · Cited by 3
The regulatory network controlling DNA damage responses in Saccharomyces cerevisiae
Fu, Y. V. (2008) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 4
Selective Constraints and Human Disease Genes: Evolutionary and Bioinformatics Approaches
Dopazo, H. (2008) · Wiley eBooks · doi:10.1002/9780470015902.a0020762 · Cited by 2
“In summary, there is a large agreement between the functional relevance of residues deduced from the estimation of selective constraints using ML models and the functional or structural importance demonstrated experimentally in p53DB domain (Cho et al., 1994).”
BackgroundAnalysis of Oncosuppressor Gene Function in the Mouse by Gene Targeting
Hooper, M. (1996) · Gene Technology · doi:10.1007/978-3-642-61122-3_19 · Cited by 2
p53: a cellular Achilles' heel revealed
Burley, S. K. (1994) · Structure · doi:10.1016/s0969-2126(94)00079-4 · Cited by 2
p53-targeted drugs: intelligent weapons in the tumor-suppressing arsenal
Papavassiliou, A. G. (2000) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050020 · Cited by 2
“Given the plethora of structural information available for the p53 molecule (Cho et al. 1994; Clore et al. 1994), structure-based drug design methodologies can assist this process by applying an ever-growing number of computational tools to the design of p53-targeted low-molecular-mass ligands that…”
MethodTung, S.-F., Chuang, J., Lin, C., Lai, M., Wu, C., & Lin, Y.-S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7748 · Cited by 2
Genetic markers to predict polygenic disease
Galton, D. J. (1999) · Current Atherosclerosis Reports · doi:10.1007/s11883-999-0004-z · Cited by 2
“For example, mutations of a tumor suppresser gene, the adenomatous polyposis coli (APC) gene, located on the long arm of chromosome 5q 21 relate to the development of colorectal cancer [9], and mutations of the tumor suppressor gene p53 relate to the development of ovarian and breast cancers [10].”
BackgroundHernandez, T., & Hainaut, P. L. (1998) · Journal of Environmental Science and Health Part C · doi:10.1080/10590509809373497 · Cited by 2
A New Set of Monoclonal Antibodies Directed to Proline-Rich and Central Regions of p53
Voeltzel, T., Morel, A., Rostan, M.-C., Ji, J., Chiodino, C., Ponchel, F., Vigouroux, J., de Fromentel, C. C., Soussi, T., & Öztürk, M. (2004) · Hybridoma and Hybridomics · doi:10.1089/hyb.2004.23.287 · Cited by 3
“(20) This observation suggests that this portion is more immunogenic than other parts of the p53 core domain, consistent with the external position of this L2 loop determined through crystallography studies.(8) Another antibody, H53C1, bound an epitope located in the second highly evolutionary conserved domain of p53.”
InfluentialTP53 as a Biomarker in Head and Neck Squamous Cell Carcinoma
Ow, & Thomas, J. O. (2011) · Cited by 2
Hodgkin's disease mimicking suppurative lymphadenitis: A fine‐needle aspiration report of five cases
Vicandi, B., Jiménez-Heffernan, J., López-Ferrer, P., Gamallo, C., & Viguer, J. M. (1999) · Diagnostic Cytopathology · doi:10.1002/(sici)1097-0339(199905)20:5<302::aid-dc11>3.0.co;2-x · Cited by 23
Structural and functional studies of proteins in cell signaling and cancer
Dovega, R. (2014) · Figshare · Cited by 2
Russo, A. D., Migliavacca, M., Zanna, I., et al. (2002) · Cancer Epidemiology and Prevention Biomarkers · Cited by 2
TP53 Tumor Suppressor Gene: Structure and Function
Jerry, D. J., & Ozbun, M. A. (2002) · Elsevier eBooks · doi:10.1016/b0-12-227555-1/00180-5 · Cited by 2
Soonnarong, R., Tungsukruthai, S., Nutho, B., Rungrotmongkol, T., Vinayanuwattikun, C., Maluangnont, T., & Pithi Chanvorachote, B. (2021) · Research Square · doi:10.21203/rs.3.rs-607927/v1 · Cited by 2
“660 661 Computational method 662 The X-ray structure of tetrameric p53 core domain was taken from the protein data 663 bank (PDB ID: 3KMD) [22].”
MethodFunctional Analysis of the Human p53 Tumor Suppressor and its Mutants Using Yeast
Inga, A., Storici, F., & Resnick, M. A. (2007) · Springer eBooks · doi:10.1007/978-1-4020-5963-6_10 · Cited by 4
Promoters for Expression of Gene Products within Neurons and Glia
Henson, J. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-478-8_8 · Cited by 3
Inactivation of Negative Growth Regulators During Neoplastic Transformation
Smolinski, K. N., & Meltzer, S. J. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-125-1_5 · Cited by 2
Irshaid, L., Clark, M. B., Fadare, O., Finberg, K. E., & Parkash, V. (2021) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000792 · Cited by 8
Molecular Diagnostics of Cancer [Working Title]
Piccaluga, P. P. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.111118 · Cited by 1
In Silico Methods and Targeted Receptors Used in Cancer Studies
Bıçak, B., & Kecel‐Gunduz, S. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_421 · Cited by 1
DNAJA: emerging targets for anti-tumor therapy
Wu, L., Xing, P., & Li, J. (2025) · Future Oncology · doi:10.1080/14796694.2025.2514417 · Cited by 2
Moses, R., Indeglia, A., Levine, A. S., Hausler, R. M., Kelly, G., Miller, S. A., Anez-Bruzual, I., Heller, M., Delgado, R., Orr, C., et al. (2026) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-26-0030 · Cited by 1
Fumani, A. E., Anvari, M., Bibalan, M. H., & Abadi, R. S. K. (2025) · Current Microbiology · doi:10.1007/s00284-025-04617-z · Cited by 1
Rani, H., Subhadarshini, S., Jolly, M. K., & Mahadevan, V. (2025) · Epigenetics & Chromatin · doi:10.1186/s13072-025-00646-x · Cited by 1
“Structural studies of the p53-DNA complex have identified that the hotspots mutations at the R248 and R273 amino acid positions influence the direct contact with DNA, whereas R249 and R282 lie near the DNA contactinter-face [8].”
Athar, H., Zulfiqar, S., Ali, A., Armaghan, M., Khan, K., Setzer, W. N., Sharifi‐Rad, J., & Călina, D. C. (2026) · Drug Development Research · doi:10.1002/ddr.70237 · Cited by 1
“Under normal conditions, p53 acts as a tumor suppressor gene involved in apoptosis, senescence, and cell cycle arrest of tumor cells (Cho et al. 1994).”
Ursu, G. M., & Zhitkovich, A. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112045 · Cited by 2
“Zn-free DNA-binding domain of p53 is unstable and misfolds, mimicking effects of the common cancer mutations in this tumor suppressor [55,56].”
Datta, A., & Doss, C. G. P. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1736501 · Cited by 1
Chatla, D., Padmavathi, P., Kola, S., et al. (2026) · Archives of Environmental Contamination and Toxicology · doi:10.1007/s00244-026-01200-w · Cited by 1
“The structures of Nrf2–PDB ID: 6QMC (Heightman et al. 2019), p53 – PDB ID: 1TUP (Cho et al. 1994), BCL-2– PDB ID: 1G5M (Petros et al. 2001), and DNMT1–PDB ID: 3PTA (Song et al. 2011) were retrieved from the Protein Data Bank and used as target receptors for molecular docking.”
Drugging p53 mutants: Recent advances using small-molecule modulation strategies
Lopes, E. A., Monteiro, T. G., & Santos, M. M. M. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119149 · Cited by 2
Rahav, G., & Bakhanashvili, M. (2013) · InTech eBooks · doi:10.5772/54220 · Cited by 1
“p53 hot spot mutants were catego‐ rized into two classes; structural and functional mutants [61].”
Shanmugavadivu, A. C., Deepika, T., Hemamalini, R., et al. (2015) · International Journal of Applied Sciences and Biotechnology · doi:10.3126/ijasbt.v3i3.13141 · Cited by 1
p53: Point Mutations, SNPs and Cancer
Fang, M., Simeonova, I., & Toledo, F. (2012) · InTech eBooks · doi:10.5772/33715 · Cited by 2
“In contrast to contact mutants, structural mutants affect the overall architecture of the DNA-binding surface and change the conformation of the protein (Cho et al., 1994).”
BackgroundPPS: A computing engine to find Palindromes in all Protein sequences
Ahmed, Z. S., Gurusaran, M., Narayana, P., et al. (2014) · Bioinformation · doi:10.6026/97320630010048 · Cited by 1
Life, career, and structural biology
Shi, Y. (2014) · Physica Scripta · doi:10.1088/0031-8949/89/6/068004 · Cited by 1
“By age 30, Pavletich had already successfully determined two landmark crystal structures: the zinc finger protein Zif268 bound to DNA in 1991 [8] as a PhD student and the tumor suppressor p53 bound to DNA in 1994 [9] as an independent investigator (figure 2).”
Rauf, S. M. A., Sahu, K. K., Tsuboi, H., Hatakeyama, N., Endou, A., Takaba, H., Carpio, C. A. D., & Miyamoto, A. (2010) · Medicinal Chemistry Research · doi:10.1007/s00044-010-9514-z · Cited by 1
“Results and discussion The initial wild-type p53-DNA complex was taken from PDB entry1tsr, chain B (Cho et al., 1994), while initial mutant R273Hp53–DNA complex was generated using a backbone dependent side chain rotamer library (Dunbrack and Karplus, 1994; Bower et al., 1997).”
MethodA Novel c-kit Positive Biphenotypic Acute Leukemia Cell Line, TMBL-1, Carrying a p53 Point Mutation
Suzuki, S., Uozumi, K., Hanada, S., Lin, X., Ohno, N., Takatsuka, Y., Takeuchi, S., Owatari, S., Takeshita, T., & Arima, T. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000068061 · Cited by 1
“6), has extensive structural defects and that defects inactivate the biological activity of p53 [50].”
BackgroundThe Role Of Redox-Sensitive Cysteines In Multi Sub-Unit Transcription Factors
Baron, B. (2014) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.888128 · Cited by 1
Chrisanthar, R. (2009) · NORA - Norwegian Open Research Archives · Cited by 1
Radioprobing the conformation of DNA in a p53-DNA complex
Karamychev, V. N., Wang, D., Mazur, S. J., Appella, E., Neumann, R. D., Zhurkin, V. B., & Panyutin, I. G. (2012) · International Journal of Radiation Biology · doi:10.3109/09553002.2012.698030 · Cited by 1
“Th e fi rst crystal structure of a complex containing the human p53DBD and a DNA binding site was resolved by X-ray crystallography more than 15 years ago (Cho et al. 1994).”
P53 gene snp investigation in squamous cell oesophageal carcinom
Luca, C., Buburuzan, L., Romanescu, D., et al. (2010) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Maeng, C. H., Lee, H. Y., Kim, Y. W., et al. (2013) · PubMed · Cited by 1
Mohammad, H. F. (2012) · EngagedScholarship @ Cleveland State University (Cleveland State University) · Cited by 1
Hot spots and single nucleotide polymorphisms on the interaction interface of RAD51 and p53 complex
Silva, K. S. F. E. (2018) · Trends in Biomedical Research · doi:10.15761/jtbr.1000104 · Cited by 1
“The transcriptional factor function exerted by p53 and its DNA binding domain makes this protein highly sensitive to mutation at this region, altering not only its ability to bind to DNA but phosphorylation patterns and interaction with its partners [66-68].”
BackgroundEssentielle Spurenelemente und toxische Metallverbindungen
Hufnagel, M., Niemand, R., Strauch, B. M., & Hartwig, A. (2019) · Chemie in unserer Zeit · doi:10.1002/ciuz.201900835 · Cited by 1
Natarajan, A., Babikir, H. A., Paulmurugan, R., & Massoud, T. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00017-8 · Cited by 1
Skern, T. (2018) · Learning materials in biosciences · doi:10.1007/978-3-319-76858-8_3 · Cited by 1
Tam, B., Lagniton, P. N. P., Luz, M. D., Zhao, B., Sinha, S., Lei, C. L., & Wang, S. M. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae400 · Cited by 2
“Deleterious missense variation can alter p53 structure and affect p53 binding to the targeted genes, leading to altered gene expression, genome instability, and oncogenesis [13, 14].”
BackgroundCowan, B. S., & Thayer, K. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146884 · Cited by 1
“Regions such as the S2-S2 ′ hairpin and H2 helix, which are directly involved in DNA complex formation [46], also displayed positive EED values for multiple Y220C drug-bound DBD constructs, evidencing the role of allosteric compounds’ capacities to rescue active-site interactions from allosteric…”
Wang, W., Sun, X., & Wu, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209846 · Cited by 2
“However, this approach was not effective for the large numbers of DNA-contacting mutants of p53 such as R273H [61,62].”
Choudhuri, S., Arvidson, K. B., & Chanderbhan, R. F. (2007) · Elsevier eBooks · doi:10.1016/b978-012370467-2/50119-x · Cited by 1
Utilizing NMR to Study the Structure of Growth-Inhibitory Proteins
Marassi, F. M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-329-1:3 · Cited by 1
“Structures of the DNA-binding domain in complex with target DNA and with p53-binding protein 2 (33,34) have been determined by X-ray crystallography.”
MethodIn Silico Analysis of the CST6 Tumor Suppressor Gene
Pavlopoulou, A., & Tsaramirsis, G. (2013) · International Journal of Systems Biology and Biomedical Technologies · doi:10.4018/ijsbbt.2013070103 · Cited by 1
The p53 Mutation Which Abrogates Trans-Activation While Maintaining Its Growth-Suppression Activity
Oh, S., & Im, M.-Y. (2000) · Molecules and Cells · doi:10.1016/s1016-8478(23)17491-7 · Cited by 1
Computational Construction of A P53 Tetrameric Structure
Thayer, K. M. (2016) · MOJ Proteomics & Bioinformatics · doi:10.15406/mojpb.2016.03.00071 · Cited by 2
“27 To assess which portion of the full sequence aligned to the structurally determined 1TUP core domain, 17 the tetramerization fragment of the helix bundle structure, 18 and the N-terminal helix bound by MDM2 23 the respective FASTA sequences were downloaded from the PDB 28 and a multiple sequence…”
BackgroundMethodTranscription Factors as Detection and Diagnostic Biomarkers in Cancer
Goh, W. L., Assah, E., Zheng, X. T., Lane, D. P., Ghadessy, F. J., & Tan, Y. N. (2017) · Springer eBooks · doi:10.1007/978-981-10-4726-8_2 · Cited by 1
P53 in Head and Neck Squamous Cell Carcinoma
Parameswaran, J., & Burtness, B. A. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_9 · Cited by 1
Low Energy Conformations for S100 Binding Peptide from the Negative Regulatory Domain of p53
Carty, R. P., Lin, B., Fridman, D., et al. (2018) · The Protein Journal · doi:10.1007/s10930-018-9799-1 · Cited by 1
C Deletion in Exon 4 Codon 63 of p53 Gene in Turkish Patients with Oral Squamous Cell Carcinoma
Tekcan, A. (2020) · Turkish Journal of Oncology · doi:10.5505/tjo.2019.2092 · Cited by 1
In Silico Modeling of Anticancer Drugs: Recent Advances
Sharma, S., & Bhatia, V. (2021) · Intelligent systems reference library · doi:10.1007/978-3-030-71975-3_10 · Cited by 1
Design, synthesis and biological evaluation of 2-pyrrolone derivatives as radioprotectors
Satoh, H., Ochi, S., Mizuno, K., Saga, Y., Ujita, S., Toyoda, M., Nishiyama, Y., Tada, K., Matsushita, Y., Deguchi, Y., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116764 · Cited by 2
Moghadam, S. A., Omar, S. I., & Tuszyński, J. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-12515-7_3 · Cited by 2
Koseki, J., Hirose, H., Konno, M., et al. (2022) · Applied Sciences · doi:10.3390/app13010510 · Cited by 1
Generation of Monospecific Peptide Antibodies to the DNA Binding Domain of p53
Huppi, K. E., Henderson, D. W., Siwarski, D. F., et al. (2000) · BioTechniques · doi:10.2144/00295rr06 · Cited by 1
Surridge, C. D. (1994) · Nature · doi:10.1038/372482a0 · Cited by 1
P53 AND REACTIVE OXYGEN SPECIES: A CONVOLUTED STORY
Liu, B. (2007) · UKnowledge (University of Kentucky) · Cited by 2
Patho)physiological function of the Multidrug Resistance protein MRP1
Renes, J. W. (2000) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1
UV Response of Mammalian p53 Tumor Supressor Gene
Mälkönen, T. (1999) · Helda - University of Helsinki Institutional Repository · Cited by 1
Marín, J. J. G., Blazquez, A. G., Serrano, M. A., Briz, Ó., Monte, M. J., & Macías, R. I. R. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0025217 · Cited by 1
The p53 Dilemma—A Case of Too Much Too Soon?
Elias, J. M. (1999) · Journal of Histotechnology · doi:10.1179/his.1999.22.2.81 · Cited by 1
DNA Recognition by NFκB and STAT Transcription Factors
Müller, C. W. (2001) · Springer eBooks · doi:10.1007/978-3-662-04645-6_8 · Cited by 6
20 Years of DNA Damage Signaling to p53
McLure, K. G., & Kastan, M. B. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_3 · Cited by 2
Protéine P53: applications cliniques
Debuire, B. (1996) · Revue Française des Laboratoires · doi:10.1016/s0338-9898(96)80030-8 · Cited by 1
The p53 Transcription Factor as Therapeutic Target in Cancer
Asker, C., Bykov, V. J. N., Méndez‐Vidal, C., Selivanova, G., Wilhelm, M., & Wiman, K. G. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18932-6_7 · Cited by 1
Inhibition of breast and prostate cancer cell growth by 3,3'-diindolylmethane and related compounds
Kotha, L. (2009) · OakTrust (Texas A&M University Libraries) · Cited by 1
Brinck, U., Schlott, T., Cordon‐Cardo, C., Stachura, J., Walz, M. K., Fischer, G., & Korabiowska, M. (2004) · PubMed · Cited by 1
Methods for the Study of Redox-Mediated Changes in p53 Structure and Function
Mann, K. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-129-1_9 · Cited by 1
Molecular mechanisms of drug resistance in a triple negative breast cancer cell model
Adams, C. (2011) · Spiral (Imperial College London) · doi:10.25560/18268 · Cited by 1
Cancer Therapy by Reactivation of the p53 Apoptosis Pathway
Stridh, H., Bykov, V. J. N., Selivanova, G., & Wiman, K. G. (2006) · Wiley eBooks · doi:10.1002/9783527619665.ch35 · Cited by 1
Morand, P., & Müller, C. W. (2005) · Springer eBooks · doi:10.1007/3-540-29623-9_2150 · Cited by 1
(1994) · Nature Structural Biology · doi:10.1038/nsb0894-487 · Cited by 1
The conformational heterogeneity of the tumor suppressor p53 is tuned by punctual mutationsPreprint
Bizzarri, A. R. (2022) · doi:10.22541/au.165823624.46566431/v1 · Cited by 1
Parallel networks that govern the transcriptional response to stress
Durham, S. A. (2022) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/9v8x-vd6d · Cited by 1
Joerger, A. C., Friedler, A., & Fersht, A. R. (2007) · Springer eBooks · doi:10.1007/978-0-387-36534-3_17 · Cited by 1
“The crystal structure of the human p53 core domain has been solved at 2.2 A resolution in complex with a consensus DNA sequence ( Cho et al., 1994 ).”
BackgroundInfluentialSerological evidence of an association betweenChlamydia pneumoniae infection and lung cancer
Laurila, A. L., Anttila, T., Läärä, E., Bloigu, A., Virtamo, J., Albanes, D., Leinonen, M., & Saikku, P. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970220)74:1<31::aid-ijc6>3.0.co;2-1 · Cited by 138
van Muyden, R. C. P. A., ter Harmsel, B. W. A., Smedts, F. M. M., Hermans, J., Kuijpers, J. C., Райхлин, Н. Т., Petrov, S., Lebedev, A., Ramaekers, F. C. S., Trimbos, J. B. M. Z., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9<1943::aid-cncr10>3.0.co;2-f · Cited by 54
Dong, Z., Crawford, H. C., Lavrovsky, V., Taub, D., Watts, R., Matrisian, L. M., & Colburn, N. H. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199707)19:3<204::aid-mc8>3.0.co;2-d · Cited by 113
Synthesis And Application Of Atp Analogs For Phosphorylation-Dependent Kinase-Substrate Crosslinking
Raghavendra, G. V., & Kumar, S. (2013)
Jabbour-Leung, N. A. (2015) · Digital Commons-TMC (Texas Medical Center)
Roh, J.-L., & Koch, W. M. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8815-6_12
“Contact mutations involve the alteration of DNA-contact residues (R248Q, R248W, R273H, and R273C), whereas, structural mutations affect residues required for the overall architecture of the DNA-binding surface of p53 (R175H, G245S, R249S, and R282W) [61].”
BackgroundGenetic studies on recurrent miscarriage
Kaare, M. (2009) · Helda - University of Helsinki Institutional Repository
P53-Mediated Apoptosis: Regulatory and Mechanistic Aspects
Haupt, Y., Rowan, S., Shaulian, E., Gottlieb, E., Yonish-Rouach, E., Vousden, K. H., & Oren, M. (1996) · Springer eBooks · doi:10.1007/978-1-4615-5895-8_5 · Cited by 1
Effects of Nutrient Deprivation on the Expression of Growth-Arrest Genes
Rees, W. D. (2005) · Oxidative stress and disease · doi:10.1201/9781420028362.ch6
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.